Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance.
Meng CY, Sun S, Liang Y, Xu H, Zhang C, Zhang M, Wang FS, Fu YX, Peng H.
Gut. 2023 Aug;72(8):1544-1554. doi: 10.1136/gutjnl-2022-327059. Epub 2022 Oct 31.
PMID:36316098
Construction of a Delivery Platform for Vaccine Based on Modified Nanotubes: Sustainable Prevention against Plant Viral Disease, Simplified Preparation Method, and Protection of Plasmid.
Liu S, Su C, Zhang D, Song Z, Wang X, Wang J, Yuan X.
Update of Perinatal Human Immunodeficiency Virus Type 1 Transmission in France: Zero Transmission for 5482 Mothers on Continuous Antiretroviral Therapy From Conception and With Undetectable Viral Load at Delivery.
Sibiude J, Le Chenadec J, Mandelbrot L, Hoctin A, Dollfus C, Faye A, Bui E, Pannier E, Ghosn J, Garrait V, Avettand-Fenoel V, Frange P, Warszawski J, Tubiana R.
Clin Infect Dis. 2023 Feb 8;76(3):e590-e598. doi: 10.1093/cid/ciac703.